Browse the corpus

Intensive Care Med Intensive Care Med Intensive Care Medicine 0342-4642 1432-1238 Springer-Verlag Berlin/Heidelberg 8814477 BF01708102 10.1007/BF01708102 Brief Report Surfactant replacement therapy in acute respiratory distress syndrome from viral pneumonia Putz G. 1 Hrmann C. 1 Koller W. 1 Schn G. 2 1 Division of Surgical and General Intensive Care Medicine, Clinic for Anesthesia and General Intensive Care Medicine, Anichstr. 35, A-6020 Innsbruck, Austria 2 Clinic for Radiodiagnostic, Innsbruck, Austria 1996 22 6 588 590 16 9 1994 12 9 1995 Springer-Verlag 1996This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.A modified natural surfactant was administered to a patient with life-threatening adult respiratory distress sydrome caused by viral pneumonia. Subsequently, there was a marked improvement in gas exchange. In order to assess the mechanism for improved oxygenation, computed tomography of the lungs was done. Quantitative analysis of the scans taken before and after surfactant administration indicates that improvement in gas exchange was largely due to the expansion of underinflated and collapsed lung areas. Although this is a single case report, it provides insight into the possible beneficial effect of instilled surfactant in severe respiratory distress from viral pneumonia.

ter surfactant administration indicates that improvement in gas exchange was largely due to the expansion of underinflated and collapsed lung areas. Although this is a single case report, it provides insight into the possible beneficial effect of instilled surfactant in severe respiratory distress from viral pneumonia. Key words ARDSPneumoniaPulmonary surfactantsSurfactant replacement therapyissue-copyright-statement Springer-Verlag 1996